


HEALTHCARE

Innovation in Drug Delivery

The future of nanotechnology and non-invasive protein delivery

By Sarah Riley

 [Table of Contents](#)

Sarah Riley

Sarah Riley is an analyst within the healthcare function of Business Insights. She has a PhD in physiology from King's College, London and is an expert in autoimmune diseases and cardiology. She has previously worked on commercial analyses of the diabetes market, the future of the monoclonal antibodies market and pharmaceutical licensing strategies.

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Innovation in drug delivery

Executive Summary 10

| | |
|---|-----------|
| Introduction | 10 |
| Advances in nanotechnology | 11 |
| Targeted therapies in oncology | 12 |
| Innovation in pulmonary delivery | 13 |
| Innovation in transdermal delivery | 14 |
| Innovation in medical devices: stents and implants | 15 |
| Competitive landscape | 16 |
| The future of drug delivery | 17 |

Chapter 1 Introduction 20

| | |
|---|-----------|
| Summary | 20 |
| Introduction | 21 |
| Key indications | 21 |
| Key trends | 22 |
| Cost and revenue implications of innovative technology | 23 |
| Drivers of innovation | 24 |
| Poor patient compliance and injectable protein delivery | 24 |
| Needle-free injections | 24 |
| Non-invasive protein delivery | 25 |
| Poor solubility | 25 |
| Formulation technologies for poorly soluble compounds | 26 |
| Reducing drug dosage frequency | 26 |
| Combination products | 26 |
| Controlled release | 27 |
| Conclusions and key findings | 28 |

Chapter 2 Advances in nanotechnology 32

| | |
|--|-----------|
| Summary | 32 |
| Introduction | 33 |
| Advantages of nanotechnology for drug delivery | 33 |
| Marketed products using nanotechnology | 35 |
| Abraxane | 35 |
| Doxil | 36 |
| Potential for nanotechnology in drug delivery | 37 |
| Injectable delivery | 38 |
| Implantable delivery systems | 38 |
| Oral delivery | 39 |
| Transdermal delivery | 39 |
| Competitive landscape | 40 |
| Elan | 40 |
| Flamel Technologies | 41 |
| Michigan Nanotechnology Institute for Medicine and Biological Sciences | 42 |
| Abraxis BioScience | 43 |
| Others | 43 |
| The future of nanotechnology in drug delivery | 44 |
| Delivering cancer stem cell therapies | 44 |
| siRNA and gene therapy | 45 |
| Conclusions and key findings | 45 |

Chapter 3 Targeted therapies in oncology 48

| | |
|---|-----------|
| Summary | 48 |
| Introduction | 49 |
| Targeted therapies overview | 49 |
| Nanotechnologies to target cancers | 50 |
| Stealth | 51 |
| Transdrug | 52 |
| NanoCrystal | 52 |
| Monoclonal antibodies | 53 |
| Pipeline mAbs | 54 |
| Antibody fragments | 56 |
| PEGylation | 56 |
| UniBody technology | 57 |
| Inhaled monoclonal antibodies | 57 |
| Oral monoclonal antibodies | 58 |
| Drug delivery to brain tumors | 58 |
| Stem cell therapy | 59 |
| Synthetic toxins | 59 |

| | |
|---|------------|
| Key M&A and licensing activity | 120 |
| Drug delivery business strategy | 120 |
| M&A activity in drug delivery | 121 |

Chapter 8 The future of drug delivery 124

| | |
|-------------------------------------|------------|
| Summary | 124 |
| Introduction | 125 |
| Nanotechnology | 126 |
| siRNA | 127 |
| Stem cells | 128 |
| Transmucosal drug delivery | 129 |
| Conclusions and key findings | 131 |

Chapter 9 Appendix 134

| | |
|---------------------|------------|
| IMS data | 134 |
| Bibliography | 134 |
| Index | 136 |

List of Figures

| | | |
|--------------|--|-----|
| Figure 1.1: | Drivers of innovation in drug delivery | 24 |
| Figure 2.2: | Sales of Abraxane, Taxol and generic paclitaxol in the US and 5EU, 2005-6 | 36 |
| Figure 2.3: | Doxil structure | 37 |
| Figure 3.4: | Targeted oncology pipeline by indication, 2006 | 50 |
| Figure 3.5: | Sales of marketed oncology mAbs, 2004-5 | 54 |
| Figure 4.6: | Inhaled insulin market forecast, 2006-2015 | 70 |
| Figure 4.7: | Aradigm pain management AERx device | 74 |
| Figure 4.8: | Sales forecasts of MedImmunes FluMist and CAIV-T in the US, 2004-2011 | 76 |
| Figure 5.9: | Transdermal drug delivery pipeline by therapy area, 2006 | 82 |
| Figure 5.10: | ALZA's E-TRANS delivery system | 87 |
| Figure 6.11: | Biophan's nanomagnetic particle-based technology | 95 |
| Figure 7.12: | Capabilities of leading innovative drug delivery companies, 2006 | 108 |
| Figure 7.13: | Licensing and collaboration strategy of leading innovative drug delivery companies | 121 |

List of Tables

| | | |
|-------------|--|-----|
| Table 1.1: | Key companies specializing in long-acting injection technology | 27 |
| Table 2.2: | Nanoparticles as drug delivery carriers | 34 |
| Table 2.3: | Sales of cancer nanomedicine marketed products in the US and 5EU, 2005-6 | 35 |
| Table 2.4: | Key nanotechnology/nanomedicine deals, 2005-2006 | 38 |
| Table 2.5: | Sales of marketed products using Elan's NanoCrystal technology in the US and 5EU, 2005-6 | 40 |
| Table 2.6: | Flamel's product pipeline using the Medusa platform, 2006 | 42 |
| Table 3.7: | Key pipeline oncology drugs using nanotechnology, 2006 | 51 |
| Table 3.8: | Late stage oncology monoclonal antibody pipeline, 2006 | 55 |
| Table 3.9: | Antibody fragment pipeline, 2006 | 56 |
| Table 3.10: | Chemotherapeutic siRNA targets | 61 |
| Table 4.11: | Key pulmonary/inhalable delivery pipeline, 2006 | 67 |
| Table 4.12: | Key pulmonary insulin pipeline, 2006 | 71 |
| Table 5.13: | Key late-stage transdermal patches, 2006 | 83 |
| Table 5.14: | Transdermal patch technology companies, 2006 | 84 |
| Table 6.15: | Key clinical trial with drug-eluting stents, 2006 | 98 |
| Table 6.16: | Comparison of costs for bare-metal and drug-eluting coronary stents, 2004 | 99 |
| Table 6.17: | Drug eluting stent pipeline, 2006 | 100 |
| Table 7.18: | Altea Therapeutic's pipeline, 2006 | 109 |
| Table 7.19: | ALZA's core technologies, 2006 | 111 |
| Table 7.20: | ALZA Therapeutics' pipeline, 2006 | 111 |
| Table 7.21: | ALZA's drug delivery deals, 2005-6 | 112 |
| Table 7.22: | Elan's R&D pipeline, 2006 | 114 |
| Table 7.23: | Elan's drug delivery deals, 2005-6 | 115 |
| Table 7.24: | Emisphere's pipeline, 2006 | 117 |
| Table 7.25: | Emisphere's drug delivery deals, 2005-6 | 117 |
| Table 7.26: | Nektar's key innovative pipeline products, 2006 | 119 |
| Table 7.27: | Nektar Therapeutics' drug delivery deals, 2005-6 | 119 |
| Table 7.28: | Drug discovery and technology deals made by the top 20 pharmaceutical companies, 2000-04 | 120 |
| Table 7.29: | Key drug delivery M&A activity, 2006 | 122 |